Evidence map›Paper›PMID 28056528›Full record

Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018

Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.

Zhiping Guo, Linhua Yang, Xiuyu Qin, Xiue Liu, Yaofang Zhang

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Variant spectrum ofFrontiers in genetics · 2023
    Article
  4. Research and practice in thrombosis and haemostasis · 2022
    Article
  5. Article
  6. Turkish journal of haematology : official journal of Turkish Society of Haematology · 2020
    Article
  7. Mutational Profiles ofMediterranean journal of hematology and infectious diseases · 2018
    Article
  8. Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zhiping Guo1 Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.
Linhua Yang1 Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.
Xiuyu Qin1 Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.
Xiue Liu1 Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.
Yaofang Zhang1 Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.
Shanxi Medical University · CNSecond Hospital of Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia A (HA) is an X-linked bleeding disorder caused by heterogeneous mutations in the factor VIII gene ( F8). Our aim is to identify the causative mutations in a large HA cohort from China. We studied 216 unrelated HA families. Molecular analyses of F8 were performed using a combination of molecular techniques, including polymerase chain reaction, direct sequencing, and multiplex ligation-dependent probe amplification. The deleterious consequences of the unreported missense mutations were evaluated using various bioinformatics approaches. Causative mutations in F8 were identified in 209 families, intron 22 inversion (Inv22) was identified in 89 severe families, and intron 1 inversion (Inv1) was positive in 5 severe families; 95 mutations were detected among 115 noninversion families, of which 42 were novel, including 29 null variations and 13 missense mutations for which causality was demonstrated via bioinformatics. Among the 53 previously reported mutations, more nonsense (5 of 9) and missense (10 of 26) mutation sites were found to occur at Arginine (Arg) sites and multiple small deletions/insertions (5 of 10) located within the poly-A runs of the B domain. The majority of these sequence variants frequently recurred in the database. The odds ratios for the likelihood of developing inhibitors significantly increased in the presence of nonsense mutation. Our F8 defect spectrum was heterogeneous. Small deletions/insertions in the poly-A runs of the B domain and nonsense and missense mutations at Arg sites were identified as mutation hot spots. Nonsense mutation increased the risk of developing inhibitors.

Indexed as

FamilyMutationPolymorphism, Single NucleotideAdolescentAdultAsian PeopleChildChild, PreschoolChinaFactor VIIIFemaleHemophilia AHumansInfantMaleMiddle AgedF8 protein, humanFactor VIIIbioinformaticsChinacoagulation factor VIII genehemophilia Ainhibitorsmutation

Identifiers

PMID28056528
PMCPMC6714629
OpenAlexW2568276637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.